Providence Therapeutics is a clinical-stage mRNA platform company developing vaccines for cancers and infectious diseases. Our scalable, efficient platform demonstrates differentiated capabilities in mRNA design, manufacturing, and formulation processes, as well as specific organ and tissue targeting. We are building a portfolio of oncology vaccines while concurrently advancing our lead asset PTX-COVID19, a COVID-19 vaccine candidate, toward Phase 3 clinical trials. Additionally, we're pursuing vaccine programs for infectious diseases that pose public health risks, including rabies. For more information, please visit providencetherapeutics.com.